309 related articles for article (PubMed ID: 30360723)
1. A Critique of Computer Simulation Software's Used in Pharmacokinetics and Pharmacodynamics Analysis.
Dave V; Yadav RB; Yadav S; Sharma S; Sahu RK; Ajayi AF
Curr Clin Pharmacol; 2018; 13(4):216-235. PubMed ID: 30360723
[TBL] [Abstract][Full Text] [Related]
2. A survey of population analysis methods and software for complex pharmacokinetic and pharmacodynamic models with examples.
Bauer RJ; Guzy S; Ng C
AAPS J; 2007 Mar; 9(1):E60-83. PubMed ID: 17408237
[TBL] [Abstract][Full Text] [Related]
3. In Silico Absorption, Distribution, Metabolism, Excretion, and Pharmacokinetics (ADME-PK): Utility and Best Practices. An Industry Perspective from the International Consortium for Innovation through Quality in Pharmaceutical Development.
Lombardo F; Desai PV; Arimoto R; Desino KE; Fischer H; Keefer CE; Petersson C; Winiwarter S; Broccatelli F
J Med Chem; 2017 Nov; 60(22):9097-9113. PubMed ID: 28609624
[TBL] [Abstract][Full Text] [Related]
4. Pharmacometrics: modelling and simulation tools to improve decision making in clinical drug development.
Gieschke R; Steimer JL
Eur J Drug Metab Pharmacokinet; 2000; 25(1):49-58. PubMed ID: 11032091
[TBL] [Abstract][Full Text] [Related]
5. PK/DB: database for pharmacokinetic properties and predictive in silico ADME models.
Moda TL; Torres LG; Carrara AE; Andricopulo AD
Bioinformatics; 2008 Oct; 24(19):2270-1. PubMed ID: 18684738
[TBL] [Abstract][Full Text] [Related]
6. Population stochastic modelling (PSM)--an R package for mixed-effects models based on stochastic differential equations.
Klim S; Mortensen SB; Kristensen NR; Overgaard RV; Madsen H
Comput Methods Programs Biomed; 2009 Jun; 94(3):279-89. PubMed ID: 19268387
[TBL] [Abstract][Full Text] [Related]
7. Non-linear mixed-effects pharmacokinetic/pharmacodynamic modelling in NLME using differential equations.
Tornøe CW; Agersø H; Jonsson EN; Madsen H; Nielsen HA
Comput Methods Programs Biomed; 2004 Oct; 76(1):31-40. PubMed ID: 15313540
[TBL] [Abstract][Full Text] [Related]
8. Exploratory population pharmacokinetics (e-PPK) analysis for predicting human PK using exploratory ADME data during early drug discovery research.
Tabata K; Hamakawa N; Sanoh S; Terashita S; Teramura T
Eur J Drug Metab Pharmacokinet; 2009; 34(2):117-28. PubMed ID: 19645221
[TBL] [Abstract][Full Text] [Related]
9. Integration of dissolution into physiologically-based pharmacokinetic models III: PK-Sim®.
Willmann S; Thelen K; Lippert J
J Pharm Pharmacol; 2012 Jul; 64(7):997-1007. PubMed ID: 22686345
[TBL] [Abstract][Full Text] [Related]
10. DallphinAtoM: Physiologically based pharmacokinetics software predicting human PK parameters based on physicochemical properties, in vitro and animal in vivo data.
Choi S; Han S; Lee SJ; Lim B; Bae SH; Han S; Yim DS
Comput Methods Programs Biomed; 2022 Apr; 216():106662. PubMed ID: 35151112
[TBL] [Abstract][Full Text] [Related]
11. Software for population pharmacokinetics and pharmacodynamics.
Aarons L
Clin Pharmacokinet; 1999 Apr; 36(4):255-64. PubMed ID: 10320948
[TBL] [Abstract][Full Text] [Related]
12. A4S: a user-friendly graphical tool for pharmacokinetic and pharmacodynamic (PK/PD) simulation.
Germani M; Del Bene F; Rocchetti M; Van Der Graaf PH
Comput Methods Programs Biomed; 2013 May; 110(2):203-14. PubMed ID: 23182621
[TBL] [Abstract][Full Text] [Related]
13. Xpose--an S-PLUS based population pharmacokinetic/pharmacodynamic model building aid for NONMEM.
Jonsson EN; Karlsson MO
Comput Methods Programs Biomed; 1999 Jan; 58(1):51-64. PubMed ID: 10195646
[TBL] [Abstract][Full Text] [Related]
14. Influencing Factors of the Pharmacokinetic Characters on Nanopharmaceutics.
Ji X; Lu W; Wu K; Cho WC
Pharm Nanotechnol; 2017; 5(1):24-31. PubMed ID: 28948908
[TBL] [Abstract][Full Text] [Related]
15. Overview of model-building strategies in population PK/PD analyses: 2002-2004 literature survey.
Dartois C; Brendel K; Comets E; Laffont CM; Laveille C; Tranchand B; Mentré F; Lemenuel-Diot A; Girard P
Br J Clin Pharmacol; 2007 Nov; 64(5):603-12. PubMed ID: 17711538
[TBL] [Abstract][Full Text] [Related]
16. A Bayesian approach for PK/PD modeling with PD data below limit of quantification.
Zhou H; Hartford A; Tsai K
J Biopharm Stat; 2012; 22(6):1220-43. PubMed ID: 23075019
[TBL] [Abstract][Full Text] [Related]
17. Building population pharmacokinetic--pharmacodynamic models. I. Models for covariate effects.
Mandema JW; Verotta D; Sheiner LB
J Pharmacokinet Biopharm; 1992 Oct; 20(5):511-28. PubMed ID: 1287200
[TBL] [Abstract][Full Text] [Related]
18. Programming of a flexible computer simulation to visualize pharmacokinetic-pharmacodynamic models.
Lötsch J; Kobal G; Geisslinger G
Int J Clin Pharmacol Ther; 2004 Jan; 42(1):15-22. PubMed ID: 14756382
[TBL] [Abstract][Full Text] [Related]
19. PKSolver: An add-in program for pharmacokinetic and pharmacodynamic data analysis in Microsoft Excel.
Zhang Y; Huo M; Zhou J; Xie S
Comput Methods Programs Biomed; 2010 Sep; 99(3):306-14. PubMed ID: 20176408
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics-pharmacodynamics, computer decision support technologies, and antimicrobial stewardship: the compass and rudder.
Owens RC; Bulik CC; Andes DR
Diagn Microbiol Infect Dis; 2018 Aug; 91(4):371-382. PubMed ID: 29776710
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
